This phase 2 trial tests whether adding ramucirumab to the standard drug osimertinib helps people with advanced EGFR-mutant lung cancer live longer without their disease worsening. About 160 patients will receive either the combination or osimertinib alone. The study aims to see …
Phase: PHASE2 • Sponsor: Xiuning Le • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC